Background Female sexual dysfunction (FSD) is a highly prevalent condition. Nevertheless,
the scientific literature has only recently begun to accumulate evidence for treatment …

Introduction Sexual dysfunction is one of the most frequently occurring side-effects of
antipsychotic medication, impacting both quality of life and adherence to treatment. Despite …

Introduction Female sexual dysfunction (SD) is an under-recognized and undertreated
problem in patients with systemic autoimmune rheumatic disorders (SARDs). Objectives To …

Background In 1999, 1 year after the approval of the first oral phosphodiesterase type 5
(PDE5) inhibitor for the treatment of erectile dysfunction (ED), the first Princeton Consensus …

Multiple sclerosis (MS) is a relatively frequent inflammatory autoimmune illness of the central
nervous system affecting about 2.5 million people around the world, and represents the most …

Introduction: Female sexual dysfunction (FSD) is a highly prevalent, yet commonly
underdiagnosed and undertreated condition. This paper reviews the diagnostic terminology …

Female sexual disorders (FSD) are a spectrum of disorders common among women,
especially in their middle age, which can reduce the female quality of life substantially. We …

Introduction Prior consensus meetings have addressed the relationship between
phosphodiesterase type 5 (PDE5) inhibition and cardiac health. Given significant …

Female genital arousal disorder is considered to be the inability to develop or maintain
adequate genital responses, including vulvovaginal lubrication, engorgement of the …

Background Few studies have investigated the role of the phosphodiesterase type 5A
(PDE5A) isoenzyme in female genital tissue disorders, exclusively taken from cadavers, as …